Product Description
BeiGene is developing BG-C137, an Anti-FGFR2b Antibody Drug Conjugate to treat solid tumors. (Sourced from: https://clinicaltrials.gov/study/NCT06625593)
Mechanisms of Action: FGFR2 Inhibitor
Novel Mechanism: No
Modality: Antibody Drug Conjugate
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: BeiGene
Company Location: GRAND CAYMAN E9 KY1-1108
Company CEO: John V. Oyler
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|